Artelo Biosciences (ARTL) Competitors $1.01 +0.03 (+3.06%) Closing price 03:57 PM EasternExtended Trading$1.02 +0.01 (+1.49%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. SYBX, NXTC, IMNN, NERV, RLYB, RLMD, ABVC, LSB, ATHA, and BGXXShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Synlogic (SYBX), NextCure (NXTC), Imunon (IMNN), Minerva Neurosciences (NERV), Rallybio (RLYB), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), Lakeshore Biopharma (LSB), Athira Pharma (ATHA), and Bright Green (BGXX). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Synlogic NextCure Imunon Minerva Neurosciences Rallybio Relmada Therapeutics ABVC BioPharma Lakeshore Biopharma Athira Pharma Bright Green Synlogic (NASDAQ:SYBX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends. Which has more risk and volatility, SYBX or ARTL? Synlogic has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SYBX or ARTL? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 3.0% of Synlogic shares are held by company insiders. Comparatively, 0.8% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SYBX or ARTL more profitable? Artelo Biosciences' return on equity of -104.59% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -207.84% -114.81% Artelo Biosciences N/A -104.59%-94.06% Do analysts rate SYBX or ARTL? Artelo Biosciences has a consensus price target of $5.50, indicating a potential upside of 444.55%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Which has stronger earnings & valuation, SYBX or ARTL? Artelo Biosciences has lower revenue, but higher earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$8K1,688.61-$57.28M-$2.51-0.46Artelo BiosciencesN/AN/A-$9.29M-$3.05-0.33 Does the MarketBeat Community prefer SYBX or ARTL? Synlogic received 281 more outperform votes than Artelo Biosciences when rated by MarketBeat users. However, 78.13% of users gave Artelo Biosciences an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% Artelo BiosciencesOutperform Votes5078.13% Underperform Votes1421.88% Does the media refer more to SYBX or ARTL? In the previous week, Artelo Biosciences had 5 more articles in the media than Synlogic. MarketBeat recorded 7 mentions for Artelo Biosciences and 2 mentions for Synlogic. Synlogic's average media sentiment score of 1.44 beat Artelo Biosciences' score of 0.21 indicating that Synlogic is being referred to more favorably in the media. Company Overall Sentiment Synlogic Positive Artelo Biosciences Neutral SummaryArtelo Biosciences beats Synlogic on 10 of the 17 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.31M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.357.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.256.486.734.25Net Income-$9.29M$143.41M$3.22B$248.18M7 Day Performance-1.94%2.30%1.58%1.25%1 Month Performance17.43%7.14%4.05%3.76%1 Year Performance-26.28%-2.61%15.75%5.28% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.4642 of 5 stars$1.01+3.1%$5.50+444.6%-28.8%$3.31MN/A-0.355Analyst ForecastGap UpSYBXSynlogic2.4415 of 5 stars$1.12-3.8%N/A-36.3%$13.10M$8,000.00-0.2780Short Interest ↓Positive NewsGap DownNXTCNextCure4.6506 of 5 stars$0.46+1.0%$3.50+653.0%-61.5%$13.04MN/A-0.2290Earnings ReportShort Interest ↓News CoveragePositive NewsGap DownIMNNImunon2.7305 of 5 stars$0.86-2.0%$21.50+2,400.0%-35.9%$12.57M$500,000.00-0.4630Short Interest ↓NERVMinerva Neurosciences3.803 of 5 stars$1.76flat$5.00+184.1%-29.2%$12.31MN/A-4.009RLYBRallybio2.3249 of 5 stars$0.29-4.0%$10.00+3,332.9%-83.3%$12.12M$636,000.00-0.1840Upcoming EarningsRLMDRelmada Therapeutics4.3472 of 5 stars$0.36-44.6%$4.25+1,090.1%-91.1%$11.85MN/A-0.1210Upcoming EarningsHigh Trading VolumeABVCABVC BioPharma0.7582 of 5 stars$1.00+2.4%N/A-15.2%$11.71M$509,589.00-1.1630Earnings ReportGap DownLSBLakeshore Biopharma1.3868 of 5 stars$1.24+1.6%N/AN/A$11.54M$672.27M0.00773Short Interest ↓Positive NewsGap UpATHAAthira Pharma3.2025 of 5 stars$0.29+3.4%$13.83+4,605.2%-85.7%$11.48MN/A-0.1040Positive NewsBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap Down Related Companies and Tools Related Companies Synlogic Alternatives NextCure Alternatives Imunon Alternatives Minerva Neurosciences Alternatives Rallybio Alternatives Relmada Therapeutics Alternatives ABVC BioPharma Alternatives Lakeshore Biopharma Alternatives Athira Pharma Alternatives Bright Green Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARTL Stock Free ARTL Stock Alerts